Dose-Dependent Response to Phenylpropanolamine: Inhibition of Orthostasis

Publisher Website
Google Scholar
Abstract
Phenylpropanolamine, a widely consumed over‐the‐counter drug, is known to elevate blood pressure, but the mechanism is unknown; it may be both a direct and indirect sympathomimetic. This study investigated the effects of 75‐mg sustained‐release phenylpropanolamine, 75‐mg phenylpropanolamine plus 400‐mg caffeine, and 150‐mg phenylpropanolamine on blood pressure, plasma norepinephrine, and epinephrine levels in 16 normotensive subjects in a double‐blind, placebo‐controlled crossover design. Mean peak phenylpropanolamine levels of 317 ± 26, 152 ± 17, and 157 ± 17 ng/mL for 150‐mg phenylpropanolamine, 75‐mg phenylpropanolamine, and 75‐mg phenylpropanolamine plus 400‐mg caffeine, respectively, were reached at about 3.6 hours after dosing. The maximal increases in supine diastolic blood pressures after all three phenylpropanolamine‐containing drugs were almost three times that after placebo (P <.05), but peak blood pressures occurred at about 2.3 hours earlier than peak phenylpropanolamine levels. Blood pressure increases correlated with phenylpropanolamine plasma levels (r = .49 for systolic blood pressure and r = .34 for diastolic blood pressure; P <.0001 for both). Norepinephrine levels increased after the administration of 150‐mg phenylpropanolamine and 75‐mg phenylpropanolamine plus 400‐mg caffeine; norepinephrine increases correlated with phenylpropanolamine levels (r = .34, P<.0001). The expected increment in norepinephrine induced by standing was significantly decreased by phenylpropanolamine in a dose‐dependent mode. The study supports the idea that phenylpropanolamine is both a direct (at alpha‐1 and alpha‐2 receptors) and an indirect sympathomimetic agent.